November 4, 20261 min read0 views

Bitcoin long positions worth $31.86M liquidated as BTC price drops 0.56% in one hour

Moleculin's Annamycin shows promising remission rates in AML trial, data to be presented at ASH 2026.

Moleculin Biotech announced that interim results from its Phase 2/3 trial of Annamycin for relapsed or refractory acute myeloid leukemia (AML) will be presented at the 2026 ASH Annual Meeting. The trial showed remission rates of 43% and 36% in two An...

Reading Level🟢BeginnerNo prior crypto knowledge needed

Listen to this article

Moleculin's Annamycin shows promising remission rates in AML trial, data to be presented at ASH 2026.

Original Source

Pluang

Like this article

Share this article

Back to Shorts

Bitcoin Dipped Toward $76,000 and Bounced Back Above $78,000 Within Hours. Is the Bottom In?

1 min read·18m ago

Strategy raises $5.4B but barely buys bitcoin

1 min read·19m ago

Bitcoin rebounds with stocks despite threat to crypto agenda

1 min read·23m ago

Bitcoin long positions worth $31.86M liquidated as BTC price drops 0.56% in one hour

Moleculin's Annamycin shows promising remission rates in AML trial, data to be presented at ASH 2026.

Moleculin's Annamycin shows promising remission rates in AML trial, data to be presented at ASH 2026.

Related Articles

Bitcoin Dipped Toward $76,000 and Bounced Back Above $78,000 Within Hours. Is the Bottom In?

Strategy raises $5.4B but barely buys bitcoin

Bitcoin rebounds with stocks despite threat to crypto agenda

Comments